Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Background Abiraterone acetate plus prednisone and enzalutamide are both used for the
treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best …

Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …

Primary resistance to androgen receptor (AR)–directed therapies in metastatic castration-
resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with …

Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …

Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial
diagnosis; hence, androgen ablation therapy directed toward a reduction in serum …